Q4 2017 13F Holders as of 12/31/2017
-
Type / Class
-
Equity / COM
-
Number of holders
-
73
-
Total 13F shares, excl. options
-
25.8M
-
Shares change
-
-745K
-
Total reported value, excl. options
-
$211M
-
Value change
-
-$16.9M
-
Number of buys
-
33
-
Number of sells
-
-34
-
Price
-
$8.20
Significant Holders of AVADEL PHARMACEUTICALS - COM (AVDL) as of Q4 2017
90 filings reported holding AVDL - AVADEL PHARMACEUTICALS - COM as of Q4 2017.
AVADEL PHARMACEUTICALS - COM (AVDL) has 73 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 25.8M shares
.
Largest 10 shareholders include DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (3.96M shares), BRANDES INVESTMENT PARTNERS, LP (3.31M shares), Broadfin Capital, LLC (2.59M shares), PERCEPTIVE ADVISORS LLC (2.39M shares), ARMISTICE CAPITAL, LLC (1.69M shares), ACADIAN ASSET MANAGEMENT LLC (1.65M shares), MORGAN STANLEY (1.56M shares), RENAISSANCE TECHNOLOGIES LLC (1.14M shares), DEUTSCHE BANK AG\ (1.1M shares), and BROWN CAPITAL MANAGEMENT LLC (885K shares).
This table shows the top 73 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.